Phase II Study of Diclofenac Salvage in Patients Metastatic Non-Small Cell Lung Cancer With Early Signs of Progression on Single Agent PD(L)-1 Blockade
Latest Information Update: 18 Jun 2025
At a glance
- Drugs Cemiplimab (Primary) ; Diclofenac (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 12 Jun 2025 Status changed from not yet recruiting to recruiting.
- 19 Mar 2025 Planned initiation date changed from 1 Mar 2025 to 11 Apr 2025.
- 30 Jan 2025 New trial record